Benefits of Combining Beta-Blocker and Checkpoint Inhibitor

The same biochemical triggers that spur a “fight or flight” response when we encounter threats may help tumor cells to thrive.   

Roswell Park's Assistant Professor of Oncology, Shipra Gandhi, MD, and Hematology-Oncology Fellow, Manu Pandey, MBBS discuss the results of the first prospective clinical trial to show that the beta-blocker propranolol is safe in combination with pembrolizumab, an immunotherapy also known as Keytruda that has become standard therapy for patients newly diagnosed with advanced or metastatic melanoma. The researchers also document preliminary evidence that these two drugs work together to engage the immune system against tumor cells. 


Created by

Roswell Park Comprehensive Cancer Center

Related Presenters

Shipra Gandhi, MD

Shipra Gandhi, MD

Assistant Professor of Oncology
Breast and Early Phase Clinical Trials, Department of Medicine

Shipra Gandhi, MD is an Assistant professor of oncology at the Roswell Park Comprehensive Cancer Center. She completed her fellowship in hematology and oncology at Roswell Park Comprehensive Cancer Center, Buffalo, NY and recieved her board certification

Manu Pandey, MBBS

Manu Pandey, MBBS

Hematology-Oncology Fellow